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increasing the quality of life. A prospective trial to test decision 
making with the model versus a controlled group with standard 
treatment is the next step towards implementation of a decision 
support system for rectal cancer.  
 
  
 SYMPOSIUM: FUTURE RADIOTHERAPY CLINICAL 
TRIALS: SALT, PAPRIKA AND MOLECULAR SIGNA-
TURES AND RT  
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Modern radiotherapy research is built on well validated biological and 
physical hypotheses which will be tested in the clinical trial.  The trial 
design must enable the investigator to obtain a clear answer to the 
primary trial objective, through clear enunciation of the primary 
hypothesis, the endpoint to be measured and an appropriate 
statistical design to enable the hypothesis to be evaluated in a way 
which is reliable. The extreme heterogeneity of cancer is leading 
some investigators to think that conventional clinical trial 
methodology is outmoded and that fundamentally different 
approaches are required. Individualisation of therapy on the basis of 
tumour genotype, imaging or both is portrayed as the goal of modern 
cancer therapy. Individualisation of radiotherapy occurs in every case 
through the treatment planning process and within clinical trials this 
must be undertaken within the constraints of a prospectively 
optimised and agreed radiotherapy treatment protocol and 
commensurate RT quality assurance process to be delivered before 
and during the trial. Similarly biomarker or imaging based treatment 
allocation or randomisation requires the use of rigorous technical 
delivery of the assay or scan and an agreed method of interpretation 
of the outcome. In phase 1 drug radiation trials, delays while waiting 
for assessment of radiotherapy toxicity risk making such studies too 
slow and relatively early dose escalation and ‘flip-flop’design 
evaluating two novel agents in alternating dose escalation cohorts is 
an efficient design. Multi-stage trial designs can speed up the phase 
II/III evaluation of novel therapies, while enabling early termination 
for futility. The SCOPE-1 trial of the addition of cetuximab to 
chemoradiotherapy for oesophageal cancer is an example. Prospective 
molecular sstratification of patients for intervention trials relevant to 
the specific abnormalities in their tumour can be designed but require 
extensive collaboration and large numbers. Such designs are coming 
into stratified drug trials such as the FOCUS4 study in metastatic 
colorectal cancer and the applicability to radiotherapy studies will be 
discussed.  
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Integration of molecular imaging techniques into therapy selection 
strategies and radiation treatment planning can serve several 
purposes. First, pretreatment assessments can steer decisions about 
radiotherapy modifications or combinations with other modalities. 
Second, biology-based objective functions can be introduced to the 
radiation treatment planning process by co-registration of functional 
imaging with planning CT-scans. Thus, customized heterogeneous dose 
distributions can be generated with escalating doses to tumor areas 
where radiotherapy resistance mechanisms are most prevalent. Third, 
monitoring of temporal and spatial variations in these radiotherapy 
resistance mechanisms early during the treatment can discriminate 
responders from non-responders. With such information available 
shortly after the start of the treatment, modifications can be 
implemented or the radiation treatment plan can be adapted tailing 
the biological response pattern. 
Currently, these strategies are in various phases of clinical testing, 
mostly in single-center studies but more and more also in multi-center 
set-up. Ultimately, this should result in availability for routine clinical 
practice requiring stable production and accessibility of tracers, 
reproducibilty and standardization of imaging and analysis methods 
and general availability of knowledge and expertise. Small studies 
employing adaptive radiotherapy based on functional dynamics and 
early response mechanisms demonstrate promising results. This 
approach is closest to large scale clinical testing with good prospects 
for success. 
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The definition of quality in radiation therapy largely remains poorly 
defined, understood and often confused with the issues of safety.  
While safety and quality are on many levels inseparable, there is a 
clear distinction and there can be delivery of safe treatments 
according to physician prescription in radiation therapy which are of 
insufficient quality to meet the treatment goals.  High quality clinical 
operations can be defined as those which minimize variations and 
uncertainty in patient treatments and result in consistent 
outcomes. In radiation therapy, treatment consists of multiple 
components (consultation, treatment selection, immobilization, 
imaging for planning, contouring, planning, etc.).  Relatively large 
variation and uncertainty in any one of these steps contribute to the 
overall degradation of treatment quality.  The degradation of quality 
results in uncertainty in patient outcomes.  Figure 1 a) shows an 
example distribution of patient treatments.  On one end of the 
spectrum is overdose of critical structures, in middle are the majority 
of patient treatments which result in clinical benefit without 
unexpected side effects,and on the other side of the spectrum is 
under dose of target volumes.  The over dose and under dose is clearly 
bad, but the two regions between clinical benefit and over dose and 
under dose, respectively, have clinical uncertainty. Patients falling in 
these uncertainty regions may or may not have clinical complications 
or poor tumor control. Patients falling in extreme over or under dose 
regions are typically infrequent and these are extreme cases that 
typically are widely publicized.  However, it is unclear how many 
patients fall in the uncertainty regions and potentially have 
compromised outcomes.  It is important to note that the outcomes in 
the uncertainty region are often considered as expected and accepted 
treatment outcomes, though possibly avoidable. 
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Figure1. a) Clinical system with large uncertainty and overall poor 
quality, b) Clinical system with reduced uncertainty and improved 
clinical benefit (quality) for the majority of treated patients. 
Figure 1 b) shows an outcome distribution for a system with improved 
quality.  In this situation, the vast majority of patients fall in the 
clinical benefit region and the overall uncertainty of clinical outcomes 
is reduced.  The quality improvement in radiation therapy can be 
defined as an effort to move a clinical system from the situation in 
Figure 1 a) to that shown in Figure 1 b).  This quality improvement 
and consistent operational level can be achieved through systems 
management, standardization, benchmarking, and a variety of 
industrial tools.  High level of quality and reliability cannot be 
achieved without a systematic approach to operations and clinical 
management.  In many aspects, Figure 1 is overly simplistic  
representation of the actual clinical operations and other concerns 
like timely and efficient care, cost,and the overall employee and 
patient satisfaction are not considered in this example.  Systematic 
approach to clinical decisions and operational management can lead 
to improvements in all of these areas.  In fact, most modern 
radiotherapy operations are very complex, have a relatively high risk 
for catastrophic failures, and involve significant cost and as such meet 
the very definition of operations which require systems 
approach. Direct translation of industrial methods to clinical 
environment is typically inappropriate and requires adaptation to 
result in meaningful improvements in clinical operations.    
This presentation will discuss: 
1) The role of quality and safety in radiation therapy 
2) Modern approaches to quality management which are adoptable to 
radiation therapy operations 
3) The role of automation, decision support, and knowledge based 
tools for management of safety and quality in radiation therapy 
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Over the past few years, due to the development of new radiotherapy 
equipments and complex techniques such as IMRT, IGRT and IMAT, the 
amount of quality controls (QC) required to check the equipment 
performance and the patient-specific treatment plans has increased 
and could be a barrier to the development of these techniques. 
Although we can find reports or guidelines regarding the procedures, 
protocols and detectors that are best adapted for each control, it 
remains difficult to find discussions on how to improve the dose 
delivery process by reducing variability and by defining action levels. 
In this purpose, we suggest that the quality control results should not 
only be analyzed in an individual manner by checking if the result is 
within predefined tolerances, but should also be analyzed from a 
process behaviour point of view. This is done by evaluating the 
position of the current result compared to all of the previous similar 
results. This will help to detect a potential drift of the whole process 
that could be missed when evaluating each result individually. As a 
consequence, this will help to increase quality. To perform this 
process analysis, an industrial method: the Statistical Process Control 
(SPC) has been used. SPC aims at controlling and improving the quality 
of a process through statistical analysis, by using two main tools: 
control charts and performance indices. 
Control charts (see Figure 1) are graphics that monitor the process 
over time, by using statistical control limits that distinguish random 
(natural) variations (i.e values within the control limits) from 
significant changes (special causes) that disturb the process. Thanks 
to the statistical control limits, the effects of special causes can be 
detected, and then actions can be undertaken to reduce or eliminate 
their effects. A process that is only subject to random causes of 
variation around the target value (i.e the perfect value to which each 
result should tend to, for instance having 0% of deviation between 
calculation and measurement) is statistically under control and thus 
statistically predictable.  
Performance indices quantify the ability of a process to produce data 
that are within predefined tolerances, at a precise moment. They give 
a value showing how far the results are from these tolerances and/or 
from the target. So, contrary to control charts, performance indices 
depend on the tolerances that are often chosen empirically, based on 
practice and experience, and thus on the QC’s method.  
In the presentation, we will show how SPC can be used to monitor the 
IMRT pre-treatment quality controls and to make the dose delivery 
process under control. The aim is to increase the security of each 
patient’s treatment while controlling the whole dose delivery process, 
without increasing time devoted to the analysis. 
We are convinced that SPC should help to secure and to improve 
quality of many processes in radiotherapy and could serve as a 
common language to evaluate processes’ performance. Moreover, the 
ultimate goal of SPC is, considering a process is under control, to 
streamline the amount of QC in a safe statistical environment by 
taking objective decisions to balance resources and quality. 
 Figure 1: Example of a control chart displaying three potential special 
causes. This process is out of control. 
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It has been estimated (UNSCEAR, 2000) that there are worldwide 
about 2000 million X-Ray studies, 32 million nuclear medicine studoes 
and over 6 million radiation therapy treated annually, and the 
numbers are constantly increasing. 
The process of radiotherapy (RT) is complex and involves 
understanding of the principles of medical physics, radiobiology, 
radiation safety, dosimetry,radiation treatment planning, simulation 
and interaction of radiation with other treatment modalities. Each 
step in the integrated process of RT needs quality control and quality 
assurance (QA) to prevent errors and to give high confidence that 
patients will receive the prescribed treatment correctly.Recent 
advances in RT, including intensity-modulated and image-guided RT, 
focus on the need for a systematic RTQA program that balances 
patient safety and quality with available resources. It is necessary to 
develop more formal error mitigation and process analysis methods, 
such as failure mode and effect analysis, to focus available QA 
resources optimally on process components. External auditprograms 
for RT can serve to improve patient safety and quality of care, 
andthus are also effective; these can be found in some national or 
international regulatory authorities and professional societies. 
In addition to an on-site audit, an off-site audit, such as a postal 
dosimetry audit program, is necessary to assure the dose from RT 
equipment. For more than three decades, some international 
authorities and national/continental professional societies have 
operated some independent dosimetry audits (postal 
thermoluminescent dosimetry (TLD) or radiochromic films dose-
auditing programme) for more than 2000 RT institutions in 120 
countries. A global and steady improvement in the performance of 
dosimetry audits has been occurring so that ~95% of the participating 
institutions are within the 5% acceptance limit for beam calibration. 
